CytomX Therapeutics (CTMX) to Release Earnings on Thursday

Key Points

• CytomX Therapeutics is set to announce its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.05) per share and revenue of $19.10 million.
• The stock has recently traded up 7.3%, reaching $2.35, with analysts setting new price targets, most notably raising estimates to between $5.00 and $7.00.
• Institutional ownership stands at 67.77%, with Woodline Partners LP acquiring a new stake valued at approximately $1,054,000.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $19.10 million for the quarter.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. CytomX Therapeutics had a negative return on equity of 553.71% and a net margin of 28.22%. The company had revenue of $50.92 million during the quarter, compared to analysts' expectations of $35.42 million. During the same period last year, the firm earned $0.17 EPS. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock traded down $0.01 during mid-day trading on Tuesday, reaching $2.39. 329,403 shares of the company were exchanged, compared to its average volume of 3,135,653. CytomX Therapeutics has a twelve month low of $0.40 and a twelve month high of $3.10. The firm's 50-day simple moving average is $2.42 and its two-hundred day simple moving average is $1.42. The firm has a market cap of $192.28 million, a PE ratio of 4.99 and a beta of 2.13.

Wall Street Analysts Forecast Growth

CTMX has been the subject of a number of analyst reports. Wedbush reissued an "outperform" rating and set a $6.00 target price (up from $5.00) on shares of CytomX Therapeutics in a research note on Monday, May 12th. HC Wainwright raised CytomX Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a research note on Thursday, May 15th. Oppenheimer initiated coverage on CytomX Therapeutics in a research note on Thursday, July 31st. They set an "outperform" rating and a $7.00 target price for the company. Piper Sandler increased their target price on CytomX Therapeutics from $2.50 to $5.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Wall Street Zen raised CytomX Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, CytomX Therapeutics currently has an average rating of "Buy" and an average price target of $5.75.

Hedge Funds Weigh In On CytomX Therapeutics

An institutional investor recently bought a new position in CytomX Therapeutics stock. Goldman Sachs Group Inc. acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 61,719 shares of the biotechnology company's stock, valued at approximately $39,000. Goldman Sachs Group Inc. owned approximately 0.08% of CytomX Therapeutics at the end of the most recent reporting period. Institutional investors own 67.77% of the company's stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.